Adimmune (4142) Stock Overview
Engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4142 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Adimmune Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$18.25 |
| 52 Week High | NT$25.95 |
| 52 Week Low | NT$15.90 |
| Beta | 0.47 |
| 1 Month Change | -5.68% |
| 3 Month Change | -1.08% |
| 1 Year Change | -27.15% |
| 3 Year Change | -54.60% |
| 5 Year Change | -64.90% |
| Change since IPO | -73.93% |
Recent News & Updates
Recent updates
There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price Rise
Jan 13
Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues
Aug 13Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality
Apr 05Is Adimmune (TPE:4142) Using Debt In A Risky Way?
Mar 01Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years
Jan 07Shareholder Returns
| 4142 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.2% | 0.2% | -2.3% |
| 1Y | -27.1% | 9.5% | 35.1% |
Return vs Industry: 4142 underperformed the TW Biotechs industry which returned 9.5% over the past year.
Return vs Market: 4142 underperformed the TW Market which returned 35.1% over the past year.
Price Volatility
| 4142 volatility | |
|---|---|
| 4142 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4142 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4142's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | n/a | Steve Chan | www.adimmune.com.tw |
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine.
Adimmune Corporation Fundamentals Summary
| 4142 fundamental statistics | |
|---|---|
| Market cap | NT$7.86b |
| Earnings (TTM) | -NT$508.60m |
| Revenue (TTM) | NT$1.20b |
Is 4142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4142 income statement (TTM) | |
|---|---|
| Revenue | NT$1.20b |
| Cost of Revenue | NT$1.17b |
| Gross Profit | NT$32.12m |
| Other Expenses | NT$540.72m |
| Earnings | -NT$508.60m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 2.67% |
| Net Profit Margin | -42.34% |
| Debt/Equity Ratio | 66.0% |
How did 4142 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 13:31 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adimmune Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Hengyu Fu | Masterlink Securities Corp. |
| Yijun Chen | SinoPac Securities Investment Service |